According to filings with the U.S. Securities and Exchange Commission, Omniox is raising up to $28,063,773.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Omniox
Omniox is an IND-stage biotherapeutics company developing breakthrough H-NOX platform technology into first-in-class and best-in-class OMX oxygen delivery vehicles that treat a range of significant unmet medical needs. OMX biologics are engineered to deliver oxygen safely to hypoxic tissues, where abnormally low oxygen levels drive disease pathology and worsen patient outcomes. By specifically oxygenating pathologically hypoxic tissues, OMX biologics restore normal tissue function with the potential for improved outcomes and patient cures.

To learn more about Omniox, visit https://www.omniox.com/
Omniox Linkedin Page: https://www.linkedin.com/company/omniox/

Contact:
Jonathan Winger, Chief Executive Officer
917-533-8548
https://www.linkedin.com/in/jonathan-winger-4684942a/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.